公开(公告)号：US07579873B1

公开(公告)日：2009-08-25

申请号：US11985706

申请日：2007-11-16

Applicant: Bin Jiang ,  Sang Kong Chan

Inventor： Bin Jiang ,  Sang Kong Chan

IPC: H03K19/0175 ,  H03K3/00

CPC classification number: H03K5/01 ,  H03K5/06

Abstract: An interface driver circuit comprises N cascaded delay cells, each including a data bit input, a delayed data bit output that communicates with the data bit input of an adjacent one of the N cascaded delay cells, and a delay time input that sets delay values between receiving data at the data bit input and generating the delayed data bit output. N predrivers receive an output enable signal that is independent of the data, receive a corresponding one of the N delayed data bit outputs and generate a predriver output signal based on the output enable signal and the corresponding one of the N delayed data bit outputs.

Abstract translation: 一个接口驱动电路包括N个级联延迟单元，每个包括数据位输入，与N个级联延迟单元相邻的数据位输入通信的延迟数据位输出，以及延迟时间输入， 在数据位输入端接收数据并产生延迟的数据位输出。 N个预取器接收独立于数据的输出使能信号，接收N个延迟的数据位输出中的相应一个，并且基于输出使能信号和N个延迟的数据位输出中的相应一个产生预驱动输出信号。

公开(公告)号：US07569689B2

公开(公告)日：2009-08-04

申请号：US11034652

申请日：2005-01-13

Applicant: Jingwu Duan ,  Bin Jiang ,  James Sheppeck ,  John L. Gilmore

Inventor： Jingwu Duan ,  Bin Jiang ,  James Sheppeck ,  John L. Gilmore

IPC: A61K31/498 ,  C07D417/14

CPC classification number: C07D403/12 ,  C07D241/36 ,  C07D417/12 ,  C07D417/14

Abstract: A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2NR1R2 and where at least two of X1-X4 and/or X5-X8 is N or NR18, and R, Ra, Rb, Rc, Rd, R1, R2 and R18 are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

Abstract translation: 提供了一类新型非甾体化合物，其可用于治疗与糖皮质激素受体，AP-1和/或NF-κB活性的调节相关的疾病，包括肥胖症，糖尿病，炎症和免疫疾病，并且具有 式（I）其立体异构体，或其溶剂合物，或其前药，或其药学上可接受的盐，其中Z为CONR1R2或CH2NR1R2，并且其中X1-X4和/或X5-X8中的至少两个为N或NR18 ，R，R a，R b，R c，R d，R 1，R 2和R 18如本文所定义。 还提供了治疗肥胖症，糖尿病和包含所述化合物的炎性或免疫相关疾病的药物组合物和方法。

公开(公告)号：US20090075995A1

公开(公告)日：2009-03-19

申请号：US11835438

申请日：2007-08-08

Applicant: David S. Weinstein ,  Ping Chen ,  T.G. Murali Dhar ,  Jingwu Duan ,  Hua Gong ,  Bin Jiang ,  Bingwei Vera Yang ,  Arthur M. Doweyko

Inventor： David S. Weinstein ,  Ping Chen ,  T.G. Murali Dhar ,  Jingwu Duan ,  Hua Gong ,  Bin Jiang ,  Bingwei Vera Yang ,  Arthur M. Doweyko

IPC: A61K31/5377 ,  A61K31/436 ,  C07D491/052 ,  A61P31/12 ,  A61K31/427 ,  C07D417/12

CPC classification number: C07D417/12 ,  C07D277/46 ,  C07D405/12 ,  C07D417/14 ,  C07D491/04

Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including inflammatory and immune diseases, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which: Z is heterocyclo or heteroaryl; A is a 5- to 8-membered carbocyclic ring or a 5- to 8-membered heterocyclic ring; B is a cycloalkyl, cycloalkenyl, aryl, heterocyclo, or heteroaryl ring, wherein each ring is fused to the A ring on adjacent atoms and optionally substituted by one to four groups which are the same or different and are independently selected from R5, R6, R7, and R8; J1, J2, and J3 are at each occurrence the same or different and are independently -A1QA2-; Q is a bond, O, S, S(O), or S(O)2; A1 and A2 are the same or different and are at each occurrence independently selected from a bond, C1-3alkylene, substituted C1-3alkylene, C2-4alkenylene, and substituted C2-4alkenylene, provided that A1 and A2 are chosen so that ring A is a 5- to 8-membered carbocyclic or heterocyclic ring; R1 to R11 are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.

Abstract translation: 提供了新的非甾体化合物，其可用于治疗与式（I）结构的糖皮质激素受体，AP-1和/或NF-κB活性（包括炎症和免疫疾病）调节相关的疾病：对映异构体 ，非对映异构体或其互变异构体，或其前药酯或其药学上可接受的盐，其中：Z是杂环或杂芳基; A是5至8元碳环或5至8元杂环; B是环烷基，环烯基，芳基，杂环基或杂芳基环，其中每个环与相邻原子上的A环稠合并任选地被一至四个相同或不同的基团取代，并且独立地选自R5，R6， R7和R8; J1，J2和J3各自出现相同或不同，独立地为-A1QA2-; Q是键，O，S，S（O）或S（O）2; A1和A2相同或不同，并且在每次出现时独立地选自键，C1-3亚烷基，取代的C1-3亚烷基，C2-4亚烯基和取代的C2-4亚烯基，条件是选择A1和A2使得环A为 5-至8-元碳环或杂环; R1至R11如本文所定义。 还提供了使用所述化合物治疗炎性或免疫相关疾病和肥胖症和糖尿病的药物组合物和方法。

公开(公告)号：US20080310542A1

公开(公告)日：2008-12-18

申请号：US12095194

申请日：2006-11-24

Applicant: Xiqi Gao ,  Xiaohu You ,  Bin Jiang ,  Zhiwen Pan ,  Yuan Zhang

Inventor： Xiqi Gao ,  Xiaohu You ,  Bin Jiang ,  Zhiwen Pan ,  Yuan Zhang

IPC: H04L27/28

CPC classification number: H04L1/0028 ,  H04B7/0413 ,  H04B7/0456 ,  H04B7/0617 ,  H04B7/0621 ,  H04B7/0636 ,  H04L1/0003 ,  H04L1/0009 ,  H04L1/0625 ,  H04L1/0631 ,  H04L25/0204 ,  H04L25/0228 ,  H04L25/03955 ,  Y02D70/444

Abstract: An adaptive transmission scheme of the channel environment in the multi-antenna wireless transmission system can raise the spectrum use rate and power efficiency of the communication system in fast. Comparing with the traditional single antenna input and single antenna output, the channel environment in MIMO wireless communication system is more complex. When the terminal is moving, the different types of channels between terminal and base station can be gone through and then its capacity can be changed more largely. It is characterized in: at first, obtaining the statistical channel information at the receiving end using the result of channel estimation; then, quantizing and encoding the obtained statistical channel information to get feedback bit information and send the feedback bit information to the transmitting end through a feedback channel; thereby using statistical information, the sending end calculates link self-adapting control parameters, which are used for controlling coding modulation and sending the pre-code; the sending end obtains the digital base band transmission signal using a characteristic mode transmission method and a random virtual space selection transmission method, and the receiving end carries out self-adapting receiving by the same parameters.

Abstract translation: 多天线无线传输系统中的信道环境的自适应传输方案可以快速提高通信系统的频谱利用率和功率效率。 与传统的单天线输入和单天线输出相比，MIMO无线通信系统中的信道环境更加复杂。 当终端移动时，终端和基站之间的不同类型的信道可以通过，其容量可以更大地改变。 其特征在于：首先，使用信道估计结果在接收端获取统计信道信息; 然后对获得的统计信道信息进行量化和编码以获得反馈比特信息，并通过反馈信道将反馈比特信息发送到发送端; 从而使用统计信息，发送端计算用于控制编码调制和发送预编码的链路自适应控制参数; 发送端使用特征模式发送方法和随机虚拟空间选择发送方法获得数字基带发送信号，接收端通过相同的参数进行自适应接收。

公开(公告)号：US09221826B2

公开(公告)日：2015-12-29

申请号：US14005572

申请日：2012-03-16

Applicant: Stephen T. Wrobleski ,  Jagabandhu Das ,  Lidia M. Doweyko ,  Junqing Guo ,  John Hynes ,  Bin Jiang ,  James Kempson ,  Shuqun Lin ,  Steven H. Spergel ,  John S. Tokarski ,  Hong Wu ,  Bingwei Vera Yang

Inventor： Stephen T. Wrobleski ,  Jagabandhu Das ,  Lidia M. Doweyko ,  Junqing Guo ,  John Hynes ,  Bin Jiang ,  James Kempson ,  Shuqun Lin ,  Steven H. Spergel ,  John S. Tokarski ,  Hong Wu ,  Bingwei Vera Yang

IPC: A61K31/5025 ,  A61K31/675 ,  C07D487/04 ,  C07F9/6561

CPC classification number: C07D487/04 ,  C07F9/6561

Abstract: Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.

Abstract translation: 公开了式（I）的化合物及其药学上可接受的盐。 式（I）化合物抑制JAK3的酪氨酸激酶活性，从而使其可用于治疗炎性和自身免疫性疾病。

公开(公告)号：US08987268B2

公开(公告)日：2015-03-24

申请号：US14005568

申请日：2012-03-16

Applicant: Stephen T. Wrobleski ,  Jagabandhu Das ,  Jingwu Duan ,  Junqing Guo ,  John Hynes ,  Bin Jiang ,  James Kempson ,  Shuqun Lin ,  Zhonghui Lu ,  William J. Pitts ,  Steven H. Spergel ,  Hong Wu ,  Bingwei Vera Yang

Inventor： Stephen T. Wrobleski ,  Jagabandhu Das ,  Jingwu Duan ,  Junqing Guo ,  John Hynes ,  Bin Jiang ,  James Kempson ,  Shuqun Lin ,  Zhonghui Lu ,  William J. Pitts ,  Steven H. Spergel ,  Hong Wu ,  Bingwei Vera Yang

IPC: C07D487/04 ,  C07D471/04 ,  A01N43/58 ,  A61K31/50

CPC classification number: C07D487/04 ,  C07D519/00

Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.

Abstract translation: 本发明提供式I化合物及其药学上可接受的盐。 式I化合物抑制JAK3的酪氨酸激酶活性，从而使其可用于治疗炎症和自身免疫性疾病。

公开(公告)号：US08846673B2

公开(公告)日：2014-09-30

申请号：US13388700

申请日：2010-08-11

Applicant: Jingwu Duan ,  Bin Jiang ,  Zhonghui Lu

Inventor： Jingwu Duan ,  Bin Jiang ,  Zhonghui Lu

IPC: A61K31/535 ,  C07D471/04

CPC classification number: C07D471/04

Abstract: Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, (I) are useful as kinase modulators, including Btk modulation, wherein A1, A2, A3, R4 are as defined herein.

Abstract translation: 具有式（I）的化合物及其对映异构体和非对映异构体，药学上可接受的盐，（I）可用作激酶调节剂，包括Btk调节，其中A1，A2，A3，R4如本文所定义。

公开(公告)号：US20140011795A1

公开(公告)日：2014-01-09

申请号：US14005570

申请日：2012-03-16

Applicant: Stephen T. Wrobleski ,  Gregory D. Brown ,  Lidia M. Doweyko ,  Jingwu Duan ,  Junqing Guo ,  John Hynes ,  Bin Jiang ,  James Kempson ,  Shuqun Lin ,  Zhonghui Lu ,  Steven H. Spergel ,  John S. Tokarski ,  Hong Wu ,  Bingwei Vera Yang

Inventor： Stephen T. Wrobleski ,  Gregory D. Brown ,  Lidia M. Doweyko ,  Jingwu Duan ,  Junqing Guo ,  John Hynes ,  Bin Jiang ,  James Kempson ,  Shuqun Lin ,  Zhonghui Lu ,  Steven H. Spergel ,  John S. Tokarski ,  Hong Wu ,  Bingwei Vera Yang

IPC: C07D487/04 ,  C07D471/04

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D519/00

Abstract: Disclosed are compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.

Abstract translation: 公开了式（I）的化合物及其药学上可接受的盐。 式（I）化合物抑制JAK3的酪氨酸激酶活性，从而使其可用于治疗炎性和自身免疫性疾病。

公开(公告)号：US20130137235A1

公开(公告)日：2013-05-30

申请号：US13512415

申请日：2011-04-22

Applicant: Qi Yu ,  Xiangzhan Wang ,  Ning Ning ,  Jingchun Li ,  Hongdong Yang ,  Xianwei Ying ,  Weijie Zhou ,  Bin Jiang ,  Yong Wang

Inventor： Qi Yu ,  Xiangzhan Wang ,  Ning Ning ,  Jingchun Li ,  Hongdong Yang ,  Xianwei Ying ,  Weijie Zhou ,  Bin Jiang ,  Yong Wang

IPC: H01L29/66

CPC classification number: H01L29/4983 ,  H01L21/823807 ,  H01L21/823828 ,  H01L21/823864 ,  H01L29/0649 ,  H01L29/0653 ,  H01L29/7842 ,  H01L29/7843 ,  H01L29/7845 ,  H01L29/7848 ,  H01L29/7849

Abstract: A MOS transistor (60, 62) is provided. The structure of the transistor (60, 62) includes: a semiconductor substrate (10), a channel area (20, 24), source/drain regions (22, 26), a gate (30, 32), a gate insulating layer (11), a shallow trench isolation region (12), a passive layer (50, 52), and holes (40, 42) formed with a certain distance to the gate insulating layer (11). Wherein both the shapes of the holes (40, 42) and the Young's modulus' difference between the material in the holes (40, 42) and that around the holes (40, 42) contribute to the stress concentration effect, thus the stress in the channel area (20, 24) is enhanced. The structure of the transistor (60, 62) can greatly reduce the stress attenuation during the transmission from stress resource to the sensitive region, and concentrate the stress in the sensitive region. The structure can be involved in large size device, especially.

Abstract translation: 提供了MOS晶体管（60,62）。 晶体管（60,62）的结构包括：半导体衬底（10），沟道区（20,24），源极/漏极区（22,26），栅极（30,32），栅极绝缘层 （11），浅沟槽隔离区（12），钝化层（50,52）和与栅绝缘层（11）形成一定距离的孔（40,42）。 其中孔（40,42）的形状和孔（40,42）中的材料与孔（40,42）周围的材料之间的杨氏模量差都有助于应力集中效应，因此应力 增加了通道区域（20,24）。 晶体管（60,62）的结构可以大大降低从应力资源向敏感区域传输过程中的应力衰减，并将应力集中在敏感区域。 该结构可以涉及大尺寸装置，特别是。

公开(公告)号：US08304539B2

公开(公告)日：2012-11-06

申请号：US12866270

申请日：2009-02-05

Applicant: Jingwu Duan ,  David S. Weinstein ,  Bin Jiang

Inventor： Jingwu Duan ,  David S. Weinstein ,  Bin Jiang

IPC: C07D491/147 ,  C07D413/00

CPC classification number: C07D491/147

Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including metabolic and inflammatory and immune diseases or disorders, having the structure of formula (I): an enantiomer, diastereomer, or taυtomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which: Z is heterocyclo or heteroaryl; •A is a S- to 8-membered carbocyclic ring or a S- to 8-membered heterocyclic ring; B1 and B2 rings are pyridyl rings, wherein the B1 and B2 rings are each fused to the A ring and the B1 ring is optionally substituted by one to three groups which are the same or different and are independently selected from R1, R2, and R4, and the B2 ring is optionally substituted by one to three groups which are the same or different and are independently selected from R5, R7, and R3 J1, J2, and J3 are at each occurrence the same or different and are independently -A1QA2-; Q is a bond, O, S, S(O), or S(O)2; A1 and A2 are the same or different and are at each occurrence independently selected from a bond, C1-3 alkylene, substituted C1-3 alkylene, C2-4 alkenylene, and substituted C2-4 alkenylene, provided that A1 and A2 are chosen so that ring A is a 5- to 8-membered carbocyclic or heterocyclic ring; R1 to R11 are as defined herein.

Abstract translation: 提供新的非甾体化合物，其可用于治疗与调节糖皮质激素受体，AP-1和/或NF-κB活性相关的疾病或病症，包括具有结构的代谢和炎症和免疫疾病或病症 式（I）的化合物：其对映异构体，非对映异构体或其互变异构体或其前药酯或其药学上可接受的盐，其中：Z是杂环基或杂芳基; A是5至8元碳环或5至8元杂环; B1和B2环是吡啶环，其中B1和B2环各自与A环稠合，B1环任选被一至三个相同或不同并且独立地选自R 1，R 2和R 4的基团取代 并且B2环任选被一至三个相同或不同并且独立地选自R5，R7和R8的基团取代，J1，J2和J3在每次出现时相同或不同，并且独立地为-A 1 QA 2 - ; Q是键，O，S，S（O）或S（O）2; A1和A2相同或不同，并且在每次出现时独立地选自键，C1-3亚烷基，取代的C1-3亚烷基，C2-4亚烯基和取代的C2-4亚烯基，条件是A1和A2被选择为 该环A为5-至8-元碳环或杂环; R1至R11如本文所定义。